Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued ...

Benitec has been granted a Type C meeting with the U.S. Food and Drug Administration ("FDA") in the fourth quarter of 2021 The non-clinical data derived from the evaluation of BB-301 in both the ...

HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic ...

Benitec Biopharma Limited (BNTC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Benitec Biopharma ( (BNTC)) has ...

Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD ...

-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide- - BB-301 facilitated improvements ...

In other recent news, Benitec Biopharma Inc. has announced the pricing of two equity offerings aimed at raising approximately $100 million. These offerings include an underwritten public offering of 5 ...

. On November 4, an analyst at Citizens JMP raised the stock’s price target to $22 from $20 while reiterating an Outperform rating. The price target hike follows topline clinical data results that ...

HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel ...

Benitec Biopharma Inc. (NASDAQ:BNTC – Free Report) – Equities research analysts at Leerink Partnrs raised their Q3 2025 earnings per share estimates for Benitec Biopharma in a research report issued ...